Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of XEN-D0103 in Healthy Subjects
NCT02390258Phase 1Completed
- Sponsor
- Xention Ltd.
- Start
- Jul 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of S066913 in Atrial fibrillation (AFib) (9 arms), sponsored by Xention Ltd. Primary endpoint: Number of adverse events at 22 days. Started Jul 2011; status: completed.
02
Drugs
S066913
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02390258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390258.